Phase 2 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For both parts of the trial (Stage 1 and Stage 2):
- People who have been diagnosed with geographic atrophy (a condition where patches of cells in the back of the eye break down) caused by age-related macular degeneration, in the eye being studied.
For Stage 1 only:
- People whose area of eye damage meets a minimum size requirement (at least 0.5 DA, a unit used to measure damage on the retina), whether or not the damage is in the central part of the eye, as confirmed by the investigating doctor and a specialist reading centre before the study begins.
- People who do not have abnormal blood vessel growth (called choroidal neovascularization) in the eye being studied, as confirmed by the investigating doctor and a specialist reading centre before the study begins.
For Stage 2 only:
- People whose area of eye damage falls within a specific size range (between 1 and 7 DA) and is located in a particular zone near — but not yet affecting — the central part of the eye, as confirmed by the investigating doctor and a specialist reading centre before the study begins.
- People who do not have abnormal blood vessel growth in either eye, as confirmed by the investigating doctor and a specialist reading centre before the study begins.
Who may not be able to join:
- People who have a history of repeated or currently active inflammation inside or around the eye (such as uveitis or endophthalmitis) in at least one eye.
- People who have an active infection in or around either eye at the time the study begins.
- People who have a history of, or signs of, diabetic eye disease or any disease affecting the blood vessels of the retina — other than age-related macular degeneration — in at least one eye.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants Experiencing Adverse Events; Number of Participants with Abnormal Change in Physical Examinations; Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements; Change From Baseline in Electrocardiograms (ECGs); Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed; Change from baseline in Best Corrected Visual Acuity (BCVA); Change in Slit lamp biomicroscopy assessment; Change in Intraocular pressure (IOP); Change in Lens examination assessment; Change in Ophthalmoscopy assessment; Change...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.